| Health / Medical Topics |
IDEC-Y2B8
A drug used with the drug rituximab to treat certain types of B-cell non-Hodgkin lymphoma. It is also being studied in the treatment of other types of B-cell tumors. IDEC-Y2B8 contains a monoclonal antibody that binds to a protein called CD20, which is found on B cells. It also contains a radioactive substance called yttrium Y 90, which may help kill cancer cells. IDEC-Y2B8 is a type of radioimmunoconjugate. Also called Y 90 ibritumomab tiuxetan, Y 90 Zevalin, and yttrium Y 90 ibritumomab tiuxetan. (NCI Dictionary)
YOU MAY ALSO LIKE
The date and time span specifying the best time for an activity or event to begin and end.
Conforming to an ultimate standard of perfection or excellence.
Human IDE wild-type allele is located within 10q23-q25 and is approximately 122 kb in length. This allele, which encodes insulin-degrading enzyme protein,…
This gene is involved in the catabolism of insulin and other bioactive peptides.
A sustained-release drug delivery embolization system containing small polymeric beads impregnated with the anthracycline antibiotic idarubicin with potential antineoplastic activity. The beads…
The hydrochloride salt of the anthracycline antineoplastic antibiotic idarubicin. Idarubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication…
